In This Section


  • Drs. Khalili and Burdo - HIV Research

    Groundbreaking Research at Temple Paves Way for First Trial of CRISPR-Based HIV Therapy in Human Patients

    For the last seven years, researchers at the Lewis Katz School of Medicine have been developing and refining CRISPR-based gene-editing technology for the treatment of human immunodeficiency virus type 1 (HIV) infection. Out of that effort has emerged a potentially revolutionizing therapy known as EBT-101, which thanks to recent acceptance as an Investigational New Drug (IND) by the U.S. Food and Drug Administration, could become the first functional cure for chronic HIV infection. The new IND approval for EBT-101 opens the way to the first Phase 1/2 clinical trials of a CRISPR-based therapy for HIV infection. The clinical trials will be initiated and managed by Excision BioTherapeutics, Inc., which has been a major collaborator with Temple on the development of CRISPR-based systems for the treatment of HIV.

  • Dawn Marks Research Day

    Graduate Student Research Showcased During Dawn Marks Research Day

    After moving online in 2020, the annual Dawn Marks Research Day, the popular student research showcase at the Lewis Katz School of Medicine, returned in-person on August 27 for its 20th year.  

  • Joice - Student Spotlight

    Student Spotlight: Joice Kanefsky, Biomedical Sciences Program

    Joice Kanefsky, 28, is beginning her fourth year as a PhD student in the Biomedical Sciences Graduate Program at Temple University’s Lewis Katz School of Medicine. She is a native of the state of Minas Gerais in Brazil and a graduate of Universidade Federal de Minas Gerais. As president of the Graduate Student Association, she organized the Dawn Marks Research Day that was held on Friday, August 27, at Temple’s Medical Education and Research Building. Thirty-five MS, PhD, and MD/PhD students displayed posters or made oral presentations describing their research findings. Everyone from the medical school was invited to attend.

  • MERB

    OHEDI Launches an Awards Program for Those Who Go ‘Above and Beyond’

    Nominations are being accepted for a new Health Equity Leadership & Social Justice Award launched by the Office of Diversity, Inclusion and Health Equity (OHEDI). The award is designed to celebrate national heritage months by highlighting colleagues in healthcare whose work exemplifies excellence on behalf of people and groups who are underrepresented in medicine and/or disenfranchised in society.

  • Beata Kosmider

    Faculty Spotlight: Beata Kosmider, PhD

    Beata Kosmider, PhD, Associate Professor of Microbiology, Immunology, and Inflammation at the Lewis Katz School of Medicine, is researching ways to stimulate certain cells in the lungs to regenerate so they can repair injury and slow the progression of emphysema. 

  • Drs. Khalili and Burdo

    Temple Researchers Awarded Prestigious Grant from the NIH’s Martin Delaney Collaboratories for HIV Cure Research Program

    Researchers at the Lewis Katz School of Medicine  have an unprecedented opportunity to break critical ground with HIV research, thanks to a prestigious grant from the National Institutes of Health. The grant, which is part of the Martin Delaney Collaboratories for HIV Cure Research program, will provide the Temple researchers and collaborating members with $4.8 million each year for five years.

  • Drs. Langford and Kilpatrick

    Lewis Katz School of Medicine Research Enterprise Grows: Langford and Kilpatrick Promoted

    On August 11, Amy J. Goldberg, MD, FACS, Interim Dean, announced two leadership appointments that are essential to the continued growth and expansion of the Lewis Katz School of Medicine research enterprise. T. Dianne Langford, PhD, has been promoted to Associate Dean for Research and Laurie Kilpatrick, PhD, has been named Assistant Dean for Clinical Research.   

  • Dr. Skorski

    Fels and Fox Chase Researchers Highlight Roles of TET2 and DNMT3A Mutations in Personalized Medicine-Guided Synthetic Lethality Against Leukemia

    In a recent study published in Cancer Research, researchers from Fels Cancer Institute for Personalized Medicine at the Lewis Katz School of Medicine at Temple University and Fox Chase Cancer Center identified specific leukemia gene mutations and the mechanisms by which they regulate DNA repair and respond to PARP inhibitors.